Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06095115
Registration number
NCT06095115
Ethics application status
Date submitted
18/10/2023
Date registered
23/10/2023
Titles & IDs
Public title
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Query!
Scientific title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment
Query!
Secondary ID [1]
0
0
77242113PSO3001
Query!
Secondary ID [2]
0
0
77242113PSO3001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ICONIC-LEAD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Plaque Psoriasis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - JNJ-77242113
Treatment: Drugs - Placebo
Experimental: JNJ-77242113 - Adolescent and adult participants will receive JNJ-77242113 from Week 0 through Week 156. At Week 24, adult participants who are psoriasis area and severity index (PASI) 75 or investigator global assessment (IGA) score of 0 or 1 responders (that is, those who achieve an IGA score of 0 or 1 and have \>=2-grade improvement from baseline) will be re-randomized either to continue JNJ-77242113 or to placebo (and will be retreated with JNJ-77242113 upon loss of \>=50% of their Week 24 PASI improvement). Adult participants identified as both PASI 75 and IGA 0 or 1 score non-responders will continue to receive JNJ-77242113 through Week 52. From Week 52 to Week 156, all adult participants will receive JNJ-77242113. Adolescents will not participate in re-randomization regardless of their PASI score or IGA score at Week 24. Adolescents will continue to receive JNJ-77242113 from Week 0 through Week 156.
Experimental: Placebo - Adolescent and adult participants will receive JNJ-77242113 matching placebo from Week 0 to Week 16. Participants will cross-over to receive JNJ-77242113 from Week 16 through Week 156.
Treatment: Drugs: JNJ-77242113
JNJ-77242113 will be administered orally.
Treatment: Drugs: Placebo
Placebo will be administered orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>= )2-Grade Improvement From Baseline to Week 16
Query!
Assessment method [1]
0
0
Percentage of participants who achieve an IGA score of 0 or 1 and \>=2-grade improvement from baseline to Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Query!
Timepoint [1]
0
0
Baseline to Week 16
Query!
Primary outcome [2]
0
0
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Query!
Assessment method [2]
0
0
Percentage of participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Query!
Timepoint [2]
0
0
Baseline to Week 16
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving an IGA Score of 0 at Week 16
Query!
Assessment method [1]
0
0
Percentage of participants who achieve an IGA score of 0 at Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Query!
Timepoint [1]
0
0
Week 16
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving PASI 75 Response at Weeks 4 and 16
Query!
Assessment method [2]
0
0
Percentage of participants achieving PASI 75 response (\>=75% improvement in PASI from baseline) at Weeks 4 and 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Query!
Timepoint [2]
0
0
Baseline to Weeks 4 and 16
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving PASI 90 Response at Week 8
Query!
Assessment method [3]
0
0
Percentage of participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Week 8 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Query!
Timepoint [3]
0
0
Baseline to Week 8
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving PASI 100 Response at Week 16
Query!
Assessment method [4]
0
0
Percentage of participants achieving PASI 100 response (\>=100% improvement in PASI) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Query!
Timepoint [4]
0
0
Week 16
Query!
Secondary outcome [5]
0
0
Percentage of Participants Achieving Scalp-specific Investigator Global Assessment (ss-IGA) Score of 0 or 1 and >=2 Grade Improvement Baseline to Week 16
Query!
Assessment method [5]
0
0
Percentage of participants achieving ss-IGA score of 0 or 1 and \>=2 grade improvement baseline to Week 16 will be reported. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: absence of disease (0), very mild disease (1), mild disease (2), moderate disease (3), and severe disease (4).
Query!
Timepoint [5]
0
0
Baseline to Week 16
Query!
Secondary outcome [6]
0
0
Percentage of Participants Achieving Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score of 0 at Weeks 8 and 16
Query!
Assessment method [6]
0
0
Percentage of participants achieving PSSD symptom score of 0 at Weeks 8 and 16 will be reported. The PSSD includes patient-reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [6]
0
0
Weeks 8 and 16
Query!
Secondary outcome [7]
0
0
Percentage of Participants Achieving >=4-Point Improvement From Baseline in PSSD Itch Score to Weeks 4 and 16
Query!
Assessment method [7]
0
0
Percentage of participants achieving \>=4-Point improvement from baseline in PSSD itch score to Weeks 4 and 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [7]
0
0
Baseline to Weeks 4 and 16
Query!
Secondary outcome [8]
0
0
Time to Loss of PASI 75
Query!
Assessment method [8]
0
0
Time to loss of PASI 75 will be reported. Loss of PASI 75 response is defined as \<75% improvement in PASI from Week 24 up to Week 52 in an adult participant who had achieved \>=75% improvement in PASI from baseline at Week 24. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. A PASI 75 response represents at least a 75% improvement from baseline in the PASI score.
Query!
Timepoint [8]
0
0
Week 24 up to Week 52
Query!
Secondary outcome [9]
0
0
Time to Loss of PASI 90
Query!
Assessment method [9]
0
0
Time to loss of PASI 90 will be reported. Loss of PASI 90 response is defined as \<90% improvement in PASI from Week 24 up to Week 52 in an adult participant who had achieved \>=90% improvement in PASI from baseline at Week 24. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. A PASI 90 response represents at least a 90% improvement from baseline in the PASI score.
Query!
Timepoint [9]
0
0
Week 24 up to Week 52
Query!
Secondary outcome [10]
0
0
Number of Participants with Treatment-emergent Adverse Events (AEs)
Query!
Assessment method [10]
0
0
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. Treatment-emergent AEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
Query!
Timepoint [10]
0
0
Up to 160 weeks
Query!
Secondary outcome [11]
0
0
Number of Participants with Treatment-emergent Serious Adverse Events (SAEs)
Query!
Assessment method [11]
0
0
A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly. Treatment-emergent SAEs are defined as serious events between administration of study drug and after the last dose that were absent before treatment or that worsen relative to pretreatment state.
Query!
Timepoint [11]
0
0
Up to 160 weeks
Query!
Secondary outcome [12]
0
0
Change from Baseline in Body Surface Area (BSA) at Week 16
Query!
Assessment method [12]
0
0
Change from baseline in BSA to Week 16 will be reported. BSA is a commonly used measure of extent of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed (that is, plaque psoriasis).
Query!
Timepoint [12]
0
0
Baseline to Week 16
Query!
Secondary outcome [13]
0
0
Change from Baseline in PASI Total Score to Week 16
Query!
Assessment method [13]
0
0
Change from baseline in PASI total score to Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Query!
Timepoint [13]
0
0
Baseline to Week 16
Query!
Secondary outcome [14]
0
0
Percent Improvement in PASI Score From Baseline to Week 16
Query!
Assessment method [14]
0
0
Percent improvement in PASI score from baseline to Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Query!
Timepoint [14]
0
0
Baseline to Week 16
Query!
Secondary outcome [15]
0
0
Percentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and at Least a 2-grade Improvement in Genital Psoriasis From Baseline to Week 16
Query!
Assessment method [15]
0
0
Percentage of participants achieving a sPGA-G Score of 0 or 1 and at Least a 2-grade Improvement in genital psoriasis from baseline to Week 16 will be reported. The sPGA-G is a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5).
Query!
Timepoint [15]
0
0
Baseline to Week 16
Query!
Secondary outcome [16]
0
0
Percentage of Participants Achieving a Physician's Global Assessment of Hands and Feet (hf-PGA) Score of 0 or 1 and at Least a 2-grade Improvement at Week 16
Query!
Assessment method [16]
0
0
Percentage of participants achieving a hf-PGA score of 0 or 1 and at least a 2-grade improvement at Week 16 will be reported. The hf-PGA assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet as: clear (0), almost clear (1), mild (2), moderate (3), and severe (4).
Query!
Timepoint [16]
0
0
Week 16
Query!
Secondary outcome [17]
0
0
Percent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16
Query!
Assessment method [17]
0
0
Percent change from baseline in mNAPSI score at Week 16 will be reported. The mNAPSI is an index used for assessing and grading the severity of nail psoriasis. Each of the participant's 10 fingernails are evaluated for 7 features. The first3 features are each scored from 0 to 3 in severity and are (1) onycholysis and oil-drop dyschromia, (2) pitting, and (3) nail plate crumbling. The next 4 features are scored 0 - absent or 1 - present and are (1) leukonychia, (2) splinter hemorrhages, (3) nail bed hyperkeratosis, and (4) red spots in the lunula. The score ranges from 0 to 13 per nail and 0 to 130 for all fingernails.
Query!
Timepoint [17]
0
0
Baseline to Week 16
Query!
Secondary outcome [18]
0
0
Percent of Participants Achieving Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16
Query!
Assessment method [18]
0
0
Percent of participants achieving f-PGA score of 0 or 1 at Week 16 will be reported. The f-PGA is used to evaluate the current status of a participant's fingernail psoriasis on a scale of 0 to 4 (clear \[0\], minimal \[1\], mild \[2\], moderate \[3\], or severe \[4\]).
Query!
Timepoint [18]
0
0
At Week 16
Query!
Secondary outcome [19]
0
0
Change From Baseline in PSSD Symptom Score to Week 16
Query!
Assessment method [19]
0
0
Change from baseline in PSSD symptom score to Week 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [19]
0
0
Baseline to Week 16
Query!
Secondary outcome [20]
0
0
Change From Baseline in PSSD Sign Score to Week 16
Query!
Assessment method [20]
0
0
Change from baseline in PSSD sign score to Week 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [20]
0
0
Baseline to Week 16
Query!
Secondary outcome [21]
0
0
Percentage of Participants Achieving PSSD Sign Score of 0 at Week 16
Query!
Assessment method [21]
0
0
Percentage of participants achieving PSSD sign score of 0 at Week 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [21]
0
0
Week 16
Query!
Secondary outcome [22]
0
0
Percentage of Participants Achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16
Query!
Assessment method [22]
0
0
Percentage of participants achieving GenPs-SFQ Item 2 score of 0 or 1 at Week 16 will be reported. The GenPs-SFQ is a 2-item participant-reported instrument used to assess the impact of genital psoriasis on the frequency of sexual activity in the last 7 days. Item 1 assesses overall frequency of sexual activity in the last 7 days (none/zero, once, or 2 or more times), and item 2 assesses how frequently genital psoriasis symptoms have limited the frequency of sexual activity in the last 7 days (never \[0\], rarely \[1\], sometimes \[2\], often \[3\], or always \[4\]).
Query!
Timepoint [22]
0
0
Week 16
Query!
Secondary outcome [23]
0
0
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16
Query!
Assessment method [23]
0
0
Percentage of participants achieving DLQI score of 0 or 1 at Week 16 will be reported. The DLQI is a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
Query!
Timepoint [23]
0
0
Week 16
Query!
Secondary outcome [24]
0
0
Change From Baseline in Total DLQI Score at Week 16
Query!
Assessment method [24]
0
0
Change from baseline in total DLQI score at Week 16 will be reported. The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
Query!
Timepoint [24]
0
0
Baseline to Week 16
Query!
Secondary outcome [25]
0
0
Change from Baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16
Query!
Assessment method [25]
0
0
Change from baseline in domain scores of the PROMIS-29 score at Week 16 will be reported. The PROMIS-29 is a 29-item generic HRQoL survey, assessing each of the 7 PROMIS domains(depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities) with 4 questions for each domain. The questions are ranked on a 5-point Likert scale. There is also a numerical rating scale that ranges from 0 (No pain) to 10 (Worst pain imaginable) for pain intensity. The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10. Higher scores on anxiety, depression, fatigue, sleep disturbance, and pain interference indicate more severe symptoms. Higher scores on physical function and social participation indicate better health outcomes.
Query!
Timepoint [25]
0
0
Baseline to Week 16
Query!
Secondary outcome [26]
0
0
Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16
Query!
Assessment method [26]
0
0
Percentage of participants achieving CDLQI score of 0 or 1 at Week 16 will be reported. The CDLQI is an adapted version of the DLQI for the pediatric population and will be utilized in the adolescent population in this study. The adaption and validation of the CDLQI was undertaken by the original developer of the DLQI to ensure it addressed the specific needs of the pediatric population. The CDLQI is a 10-item instrument that has 4 item response options and a recall period of 1 week. Higher scores indicate greater impact on HRQoL. The instrument is designed for use in children is self-explanatory and can be simply handed to the participant who is asked to fill it in with the help of the child's parent or caregiver.
Query!
Timepoint [26]
0
0
Week 16
Query!
Secondary outcome [27]
0
0
Change From Baseline in CDLQI at Week 16
Query!
Assessment method [27]
0
0
Change from baseline in CDLQI at Week 16 will be reported. The CDLQI is an adapted version of the DLQI for the pediatric population and will be utilized in the adolescent population in this study. The adaption and validation of the CDLQI was undertaken by the original developer of the DLQI to ensure it addressed the specific needs of the pediatric population. The CDLQI is a 10-item instrument that has 4 item response options and a recall period of 1 week. Higher scores indicate greater impact on HRQoL. The instrument is designed for use in children is self-explanatory and can be simply handed to the participant who is asked to fill it in with the help of the child's parent or caregiver.
Query!
Timepoint [27]
0
0
Baseline to Week 16
Query!
Secondary outcome [28]
0
0
Change From Baseline in the Domain Scores of the PROMIS-25 Pediatric Score at Week 16
Query!
Assessment method [28]
0
0
Change from baseline in the domain scores of the PROMIS-25 pediatric score at Week 16 will be reported. The PROMIS-25 will be utilized in the adolescent population and is a 25-item generic HRQoL survey. Six PROMIS domains (physical function mobility, anxiety, depressive symptoms, fatigue, peer relationships, pain interference) are each assessed with 4 questions. There is also one 11-point rating scale for pain intensity. The instrument is designed for use in ages 8-17 years of age and can be self-administered.
Query!
Timepoint [28]
0
0
Baseline to Week 16
Query!
Secondary outcome [29]
0
0
Percentage of Participants Achieving IGA Score of 0 at Week 52
Query!
Assessment method [29]
0
0
Percentage of participants achieving IGA score of 0 at Week 52 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Query!
Timepoint [29]
0
0
Week 52
Query!
Secondary outcome [30]
0
0
Percentage of Participants Achieving PASI 100 Response at Week 52
Query!
Assessment method [30]
0
0
Percentage of participants achieving PASI 100 response (100% improvement in PASI) at Week 52 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Query!
Timepoint [30]
0
0
Week 52
Query!
Secondary outcome [31]
0
0
Time to Loss of IGA 0 to 1 Response
Query!
Assessment method [31]
0
0
Time to loss of IGA 0 to 1 response will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Query!
Timepoint [31]
0
0
Week 24 to Week 52
Query!
Secondary outcome [32]
0
0
Percentage of Adolescent Participants Achieving IGA Score of 0 or 1 and >=2 Improvement From Baseline to Week 52
Query!
Assessment method [32]
0
0
Percentage of adolescent participants achieving IGA score of 0 or 1 and IGA score \>=2 from baseline to Week 52 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Query!
Timepoint [32]
0
0
Baseline to Week 52
Query!
Secondary outcome [33]
0
0
Percentage of Adolescent Participants Achieving PASI 75 Response at Week 52
Query!
Assessment method [33]
0
0
Percentage of adolescent participants achieving PASI 75 response (\>=75% improvement in PASI from baseline) at Week 52 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Query!
Timepoint [33]
0
0
Baseline to Week 52
Query!
Secondary outcome [34]
0
0
Percentage of Adolescent Participants Achieving PASI 90 Response at Week 52
Query!
Assessment method [34]
0
0
Percentage of adolescent participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Week 52 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Query!
Timepoint [34]
0
0
Baseline to Week 52
Query!
Eligibility
Key inclusion criteria
* Diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention
* Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
* Total psoriasis area and severity index (PASI) >=12 at screening and baseline
* Total investigator global assessment (IGA) >=3 at screening and baseline
* Candidate for phototherapy or systemic treatment for plaque psoriasis
* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test beta-human chorionic gonadotropin (beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
* Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
* A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
* Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
* Major surgical procedures, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from a surgical procedure or has a surgical procedure planned during the time the participant is expected to participate in the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/10/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
6/04/2027
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
684
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Dr Rodney Sinclair Pty Ltd - East Melbourne
Query!
Recruitment hospital [2]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment hospital [3]
0
0
Kingsway Dermatology & Aesthetics - Miranda
Query!
Recruitment hospital [4]
0
0
ISHI dermatology - Mitcham
Query!
Recruitment hospital [5]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment hospital [6]
0
0
Veracity Clinical Research - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [2]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
2228 - Miranda
Query!
Recruitment postcode(s) [4]
0
0
3132 - Mitcham
Query!
Recruitment postcode(s) [5]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [6]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nebraska
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Hampshire
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Jersey
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New York
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oklahoma
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oregon
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
South Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
South Dakota
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Texas
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Utah
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Virginia
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Washington
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Buenos Aires
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Caba
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Mar Del Plata
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Rosario
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
San Fernando Buenos Aires
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Alberta
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
British Columbia
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Ontario
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Quebec
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Beijing
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Bengbu
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Cheng De Shi
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Chengdu
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Jiaxing
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Jinan
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Nan Yang Shi
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
NanChang
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Shanghai
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Shen Yang
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Wuhan
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Xi'an
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Zhenjiang
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Antony
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Argenteuil
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Bad Bentheim
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Berlin
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Bonn
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Dresden
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Dulmen
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Dusseldorf
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Frankfurt am Main
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Freiburg
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Friedrichshafen
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Heidelberg
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Mahlow
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Muenster
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Oldenburg
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Remscheid
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Tubingen
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Witten
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Wuppertal
Query!
Country [70]
0
0
Hungary
Query!
State/province [70]
0
0
Borgyogyaszati Klinika
Query!
Country [71]
0
0
Hungary
Query!
State/province [71]
0
0
Budapest
Query!
Country [72]
0
0
Hungary
Query!
State/province [72]
0
0
Debrecen
Query!
Country [73]
0
0
Hungary
Query!
State/province [73]
0
0
Kaposvar
Query!
Country [74]
0
0
Hungary
Query!
State/province [74]
0
0
Szeged
Query!
Country [75]
0
0
Hungary
Query!
State/province [75]
0
0
Szolnok
Query!
Country [76]
0
0
Hungary
Query!
State/province [76]
0
0
Veszprem
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Palermo
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Parma
Query!
Country [79]
0
0
Italy
Query!
State/province [79]
0
0
Roma
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Rozzano
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Itabashi Ku
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Kitakyushu-shi
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Mito
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Nagoya
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Osaka Sayama shi
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Sendai
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Shinjuku
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Tsu
Query!
Country [89]
0
0
Korea, Republic of
Query!
State/province [89]
0
0
Ansan-si
Query!
Country [90]
0
0
Korea, Republic of
Query!
State/province [90]
0
0
Gwangju
Query!
Country [91]
0
0
Korea, Republic of
Query!
State/province [91]
0
0
Gyeonggi-do
Query!
Country [92]
0
0
Korea, Republic of
Query!
State/province [92]
0
0
Seoul
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Bialystok
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Elblag
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Krakow
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Lodz
Query!
Country [97]
0
0
Poland
Query!
State/province [97]
0
0
Osielsko
Query!
Country [98]
0
0
Poland
Query!
State/province [98]
0
0
Poznan
Query!
Country [99]
0
0
Poland
Query!
State/province [99]
0
0
Warszawa
Query!
Country [100]
0
0
Poland
Query!
State/province [100]
0
0
Wroclaw
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
Alcorcon
Query!
Country [102]
0
0
Spain
Query!
State/province [102]
0
0
Alicante
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
Barcelona
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Bilbao
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Madrid
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Palma de Mallorca
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Santiago de Compostela
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Sevilla
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Valencia
Query!
Country [110]
0
0
Taiwan
Query!
State/province [110]
0
0
Hsin Chu
Query!
Country [111]
0
0
Taiwan
Query!
State/province [111]
0
0
Kaohsiung
Query!
Country [112]
0
0
Taiwan
Query!
State/province [112]
0
0
Taipei
Query!
Country [113]
0
0
Taiwan
Query!
State/province [113]
0
0
Taoyuan
Query!
Country [114]
0
0
Turkey
Query!
State/province [114]
0
0
Ankara
Query!
Country [115]
0
0
Turkey
Query!
State/province [115]
0
0
Kayseri
Query!
Country [116]
0
0
Turkey
Query!
State/province [116]
0
0
Samsun
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Harrow
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
London
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Reading
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Salford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06095115
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.janssen.com/clinical-trials/transparency
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06095115